About ReceptorBio
ReceptorBio is an early-stage biopharmaceutical company that is developing orally active pharmaceuticals for the treatment of insulin resistance, type 2 diabetes mellitus (T2D), and the ‘Metabolic Syndrome’, all of which are linked to a markedly increased risk of cardiovascular disease and other disorders. The Company’s initial focus will be on the clinical development of its lead compound, RB101, a late stage pre-clinical compound that activates the tyrosine kinase domain of the insulin receptor (IR), a recognized drug target for T2D. Activation of the IR is required to mediate insulin’s physiological effects on the control of blood glucose and other processes. Currently, there are no FDA-approved drugs with this mechanism of action. ReceptorBio believes its novel agent is first in class, with a mechanism of action that is compatible for use both as a single agent and in combination with existing drugs for T2D.
|
|
|
11-50 employees
View all ReceptorBio employees
|
|
Pharmaceutical Manufacturing
|
|
Redwood City, CA 94061, US
|
|
2008
|
|
Type 2 Diabetes
|
ReceptorBio Alternatives
Search ReceptorBio Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
